PPAR
Peroxisome proliferator-activated receptors
PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.
PPAR Isoform Specific Products
All Product Categories
-
PPAR Inhibitors
(100)
View all products
-
PPAR Agonists
(335)
View all products
-
PPAR Antagonists
(30)
View all products
-
PPAR Activators
(166)
View all products
-
PPAR Modulators
(38)
View all products
-
PPAR Inducers
(6)
View all products
-
PPAR Controls
(3)
View all products
-
PPAR Ligands
(4)
View all products
-
Peroxisome Proliferator-activated Receptor Proteins
(11)
View all products
-
PPAR alpha Proteins
(2)
View all products
-
PPAR gamma Proteins
(7)
View all products
-
PPAR-delta Proteins
(2)
View all products
-
PPAR Related Products (726)
Related Products (726)
-
Recombinant Proteins (11)
-
Antibodies (4)
-
PPAR Isoform Comparison
-
LY-510929
0 ImagesCat. No.: HY-120298CAS No.: 401789-93-3LY-510929 is a compound that induces left ventricular hypertrophy (LVH). Related studies have identified the relevant conditions in which LY-510929 may induce LVH by measuring multiple markers and using multiple techniques.
-
DN-108
0 ImagesCat. No.: HY-171793CAS No.: 195604-21-8DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes.
-
FSVVPSPK
0 ImagesCat. No.: HY-P11608CAS No.: 2016043-82-4FSVVPSPK is an orally active peptide. FSVVPSPK exerts significant anti-adipogenic, antioxidant and anti-inflammatory effects in vitro and in vivo, mainly through activating the HO-1/Nrf2 pathway. FSVVPSPK can be used in research related to obesity and metabolic disorders.
-
PPARα agonist 1
0 ImagesCat. No.: HY-146733CAS No.: 3032632-02-0PPARα agonist 1 is a potent and full hPPARα agonist.
-
VSP-77
0 ImagesCat. No.: HY-133559CAS No.: 1854008-12-0VSP-77 is an orally active PPARγ agonist. VSP-77 selectively upregulates the expression of insulin sensitivity-related genes (Glut4 and Adiponectin) by inhibiting CDK5-mediated phosphorylation of PPARγ at Ser-273. VSP-77 significantly improves glucose tolerance, reduces fasting blood glucose and insulin levels in high-fat diet (HFD)-induced diabetic mouse models. VSP-77 can be used for the study of diabetes.
-
D-Arabinose-d5
0 ImagesCat. No.: HY-N0059S5D-Arabinose-d5 is the deuterium labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082).
-
Rac-Pemafibrate-13C,d3
0 ImagesCat. No.: HY-17618ASSynonyms: Rac-K13675-13C,d3Rac-Pemafibrate-13C,d3 (Rac-K13675-13C,d3) is the deuterium and 13C-labeled Rac-Pemafibrate (HY-17618A). Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
-
Ciprofibrate (Standard)
0 ImagesSynonyms: Win35833 (Standard)Ciprofibrate (Standard) is the analytical standard of Ciprofibrate. This product is intended for research and analytical applications. Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias.
-
4010B-30
0 ImagesCat. No.: HY-117555CAS No.: 1415477-76-74010B-30 is a upregulator of apolipoprotein A-I (ApoA-I). 4010B-30 regulates ApoA-I gene expression through activation of PPARγ. 4010B-30 promotes cholesterol efflux and ABCA1 expression. 4010B-30 protects against atherosclerotic lesion development in ApoE-/- mice.
-
K-111
0 ImagesCat. No.: HY-120943CAS No.: 221564-97-2Synonyms: BM 17.0744K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome.
-
4,5-DiHDPA lactone
0 ImagesCat. No.: HY-124019CAS No.: 845673-68-94,5-DiHDPA lactone (5), a derivative of docosahexaenoic acid (DHA), is a PPARγ activator.
-
2'-Hydroxy-4-methoxychalcone
0 Images2'-Hydroxy-4-methoxychalcone is a PPARγ agonist. 2'-Hydroxy-4-methoxychalcone also exhibits inhibitory activity against gelatinase/collagenase and human glutathione S-transferase (GST), with an IC50 of 5.2 μM and a Ki of 15.36 μM against GST. 2'-Hydroxy-4-methoxychalcone inhibits both the NF-κB and AP-1 signaling pathways, exerting anti-inflammatory activity; it also inhibits COX-2, conferring anti-cancer/anti-angiogenic activity. 2'-Hydroxy-4-methoxychalcone can be used in studies related to atherosclerosis, inflammatory diseases and cancer.
-
PPARγ agonist 17
0 ImagesCat. No.: HY-173166CAS No.: 3054652-58-0PPARγ agonist 17 (Compound C1) is a PPARγ agonist. PPARγ agonist 17 enhances PPARγ activity and blocks the cell cycle in G2/M phase, inhibits cell migration and induces apoptosis in HT-29 cells. PPARγ agonist 17 has a broad spectrum anti-proliferative activity in cancer cells with relatively low toxicity in normal cells which cannot cross the blood-brain barrier.
-
Perfluorobutanesulfonic acid-13C3 sodium
0 ImagesCat. No.: HY-21191SCAS No.: 2708218-84-0Synonyms: PFBS-13C3 sodiumPerfluorobutanesulfonic acid-13C3 sodium (PFBS-13C3 sodium) is the 13C-labeled Perfluorobutanesulfonic acid (HY-21191). Perfluorobutanesulfonic acid (PFBS) is a short-chain perfluoroalkyl substance and the main replacement for perfluorooctanesulfonic acid. Perfluorobutanesulfonic acid induces fat accumulation in human HepG2 hepatoma cells. Perfluorobutanesulfonic acid promotes lipid accumulation by activating PPARγ pathway and triggering oxidative stress, endoplasmic reticulum stress and calcium dyshomeostasis. Perfluorobutanesulfonic acid impairs reproduction and causes developmental disorders in offspring of Caenorhabditis elegans. Perfluorobutanesulfonic acid disrupts pancreatic organogenesis and lipid homeostasis in zebrafish embryos. Perfluorobutanesulfonic acid can be used in environmental toxicology, lipid metabolism and developmental toxicity studies.
-
EPI-001 (Standard)
0 ImagesCat. No.: HY-100348RCAS No.: 227947-06-0EPI-001 (Standard) is the analytical standard of EPI-001. This product is intended for research and analytical applications. EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC50 of ~6 μM. EPI-001 is also a selective modulator of PPARγ. EPI-001 is active against castration-resistant prostate cancer.
-
PPARγ-IN-5
0 ImagesCat. No.: HY-172169CAS No.: 3038323-12-2PPARγ-IN-5 (Compound A3) is the inhibitor for PPARγ. PPARγ-IN-5 inhibits lipid accumulation in hepatocytes without significant cytotoxicity in HepG2 cell (400 µM). PPARγ-IN-5 can be used in research of non-alcoholic fatty liver disease.
-
YGT-31
0 ImagesCat. No.: HY-161926CAS No.: 2835447-74-8YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model.
